asgr1a mutants show less hepatic steatosis and lower levels of hepatic triglycerides but excrete more cholesterol in response to excess dietary cholesterol. Male zebrafish received a WD for 6 days before the blood, the liver, and the feces were collected.A, LipoGlo-Counting of plasma samples indicates B-lp quantity in asgr1a mutants and control animals. Two independent experiments, n = 2 to 3 fish each; two-way ANOVA followed by Tukey’s multiple comparison test. Experiments were normalized to their control group and shown in % to the control group. B, representative images of LipoGlo-Electrophoresis on plasma B-lps. Zero mobility and B-lp classes (VLDL, IDL, LDL) can be distinguished and analyzed. C, quantification of LipoGlo-Electrophoresis assay. Two independent experiments, n = 2 to 4 fish/genotype; two-way ANOVA followed by Tukey’s multiple comparison test. D, representative H&E images of liver steatosis. E, quantification of hepatic steatosis in asgr1ac830/c830 (13.82% ± 5.079%), asgr1ac865/c865 (12.90% ± 5.058%), and control animals (20.06% ± 7.829%). n = 9 from three independent experiments; two-way ANOVA followed by Tukey’s multiple comparison test. F, example HPLC trace of one sample of an asgr1a mutant (blue and orange) and control (black) livers. G, HPLC peak analysis of three independent experiments, n = 9, asgr1ac830/c830 (41% ± 14%) and asgr1ac865/c865 (45% ± 7.5%) mutants compared to controls (63% ± 13%). H, example HPLC trace of one sample of an asgr1a mutant (blue and orange) and control (black) fecal matter. I, peak analysis of three independent experiments, n = 9, of fecal cholesterol in asgr1ac830/c830 (83.6% ± 6.2%) and asgr1ac865/c865 (88% ± 2.6%) mutants compared to controls (52% ± 12.4%). Statistical analysis as follows: E, analyzed using two-way ANOVA followed by Tukey’s multiple comparison test. G and I, significance was computed using two Mann-Whitney U-tests with the Bonferroni correction. ∗∗ = p < 0.01; ∗∗∗∗ = p < 0.0001.
|